Depression is not only a disease of the mind or the brain, a new study finds: a research team has revealed deep connections to abnormalities in the body's overall immune response.
Biomarker testing is ushering in a novel era of therapy personalisation for gastroesophageal and colorectal cancers, according to experts presenting at the 37th European Congress of Pathology in Vienna this September. During a session on state-of-the-art in gastrointestinal biomarkers, speakers outlined how targeted therapies and immunotherapies are transforming treatment options – but…
Newly discovered blood biomarkers may offer new options to track Duchenne muscular dystrophy (DMD) in a less invasive way than physical tests or biopsies. This could support more tailored treatments.
Chronic fatigue (ME/CFS) affects millions worldwide, but is poorly understood and has long lacked reliable diagnostic tools. Now, a new blood test claims to diagnose the condition with 96% accuracy.
International research led by Leipzig and Ulm universities creates first standardized leptin reference values for all ages and weight classes, advancing personalized medicine
Scientists created precise replicas of Candida sugar coats to understand immune responses, enabling fast bedside testing that could replace slow lab cultures.
Researchers explored two promising new biomarkers as potential radiotheranostic targets for endometrial cancer. This could help identify patients who are likely to respond to targeted therapeutics.
Type 2 diabetes greatly increases the risk of heart attacks, strokes, anginas, and other coronary heart diseases. Therefore, biomarkers to predict individual risk are needed, experts say.
Do laboratory tests using blood-based biomarkers (BBB) represent the next type of universally recommended screening tests for Alzheimer's disease (AD)? Experts curb the high expectations for this type of diagnostic tool.
Using electrodes implanted in the brain, researchers observed specific brain waves that could serve as a biomarker for obsessive-compulsive disorder (OCD) and are an important step towards more targeted treatments.
The earlier Alzheimer's disease is detected, the more effective treatments become. Now, a Finnish study shows that signs related to Alzheimer’s may already be found in the brain in middle age.
Molecular markers in saliva could reveal the risk of a person developing major diseases such as cancer, cardiovascular diseases, diabetes and neurodegenerative diseases, new research finds.
What do the brains of newborns and patients with Alzheimer's disease have in common? Researchers have discovered a surprising shared trait - which might provide new insights into the disease.
In a world first, researchers have identified a set of biomarkers that could someday make it easy to spot Parkinson's disease in a patient’s blood sample.
Researchers from Université Laval discovered that the retina of people with Parkinson's disease responds differently to light than that of healthy people. This offers new diagnostic options.
A new biomarker for multiple sclerosis: the inflammatory cell rim from microglial cells surrounding brain lesions was found to directly correlate with the severity and speed of disease progression.
Pupil dilation and involuntary facial movements could provide a window into diagnosing tinnitus. A new method uses AI to detect minuscule reactions to various sounds and noises.
Using AI and extensive analyses of gene activity in tumours, researchers have found new, precise biomarkers to diagnose prostate cancer at an early stage through a simple urine sample.
A new, simpler and cheaper analytical method for the early detection of Alzheimer's disease could help bring blood tests into the healthcare system globally, according to a new study.
A large new study of more than 40,000 patients finds that a zero coronary artery calcium score continues to be an accurate indicator of a low risk for a coronary heart event even as a person ages.
A new PET tracer has the potential to play a critical role in the diagnosis, treatment, and monitoring of aggressive triple-negative breast cancer (TNBC), improving clinical outcomes for patients.
There is no known cure for Alzheimer’s disease (AD), although prescription drug-based treatments that can slow AD progression in some patients are starting to enter clinical use. Biomarkers, quantifiable characteristics of biological processes or pathological conditions of the body, are making it possible to help identify and measure the presence and extent of AD and its degenerative…
Blood-based biomarker (BBB) tests may represent the best weapon to combat the soaring rates of Alzheimer’s disease (AD) throughout the world. Existing clinically validated tests are currently deployed to facilitate diagnosis, to monitor disease and effectiveness of treatments, to quantify progression, and to determine if a patient is appropriate for treatment or participation in a clinical…
A new blood test, using neurofilament light chainproteins as biomarker, could lead to better diagnosis and management of amyotrophic lateral sclerosis (ALS).
New research highlights the potential of circulating tumor DNA (ctDNA) analysis as a non-invasive method to identify actionable biomarkers for breast cancer, enabling individualized therapies.
